|会社名||Endo International plc （エンド―・インタ―ナショナル）|
|分野（sector）||Health Care ヘルスケア|
|業種||医薬品 医療関連（Health Care）|
|概要||事業概要 エンド・インターナショナル(Endo International PLC)(旧名：Endo Health Solutions Inc.)はブランドおよびジェネリック医薬品、デバイス及びサービスの提供に集中する専門医療ソリューション会社である。同社のブランド医薬品のポートフォリオは「Lidoderm」、「Opana ER」、「Voltaren Gel」、「Percocet」、「Frova」、「Supprelin LA」、「Vantas」、「Valstar」及び「Fortesta Gel」を含む。同社はEndo医薬品事業、Qualitest事業、AMS事業、及びHealthTronics事業という４つの事業セグメントを運営する。HealthTronics事業を通じて、同社は砕石サービス、前立腺治療サービス、解剖病理学サービス、医療製品の製造・販売・保守、および情報技術ソリューションを提供する。Qualitest製品ポートフォリオには、「Endocet」、「Morphine Sulfate ER」及び「Hydrocodone」等がある。AMS事業は「AMS 700 MS」、「AMS 800」人工尿道括約筋、「GreenLight XPS」レーザーシステム及び「Monarc」筋膜下ハンモックを提供する。Endo医薬品事業は「Lidoderm」、「Opana ER」、「Voltaren Gel」及び「Percocet」等がある。 エンド―・インタ―ナショナルは医薬品企業。主な医薬品は痛みに対する治療薬、泌尿器、内分泌および腫瘍に関連する痛みのブランド治療薬、また、泌尿器、免疫抑制、腫瘍、女性特定疾患、高血圧などに対するジェネリック医薬品も含む。また、骨盤を治療する医療デバイスや技術を医師に提供。本社はアイルランドのダブリン。 Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The firm operates through the following segments: U.S. Branded-Specialty & Established Pharmaceuticals, U.S. Branded-Sterile Injectables, U.S. Generic Pharmaceuticals and International Pharmaceuticals. The U.S. Branded-Specialty & Established Pharmaceuticals segment offers prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain and orthopedics. The U.S. Branded-Sterile Injectables segment consists primarily of branded sterile injectable products such as VASOSTRICT, ADRENALIN and APLISOL, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection, among others. The U.S. Generic Pharmaceuticals segment consists of a differentiated product portfolio including solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics and sprays and includes products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health and cardiovascular disease markets, among others. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets. The company was founded in 1997 and is headquartered Dublin, Ireland.|
|本社所在地||First Floor Minerva House Simmonscourt Road Ballsbridge Dublin 4 IRL|
|代表者氏名||Roger H. Kimmel ロジャー・キンメル|
|代表者役職名||Independent Chairman of the Board|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the six months ended 30 June 2018 Endo International PLC revenues decreased 26% to $1.42B. Net loss before extraordinary items decreased 36% to $550.2M. Revenues reflect Generics segment decrease of 47% to $490.5M U.S. Branded - Specialty_Established Pharmaceuticals segment decrease of 17% to $412.9M United States segment decrease of 25% to $1.34B International segment decrease of 41% to $78.2M.|
Endo International plc Announces The Expiration And Final Tender Results Of Its Previously Announced Tender Offer 2020/08/22 00:30:00 PR Newswire
DUBLIN, Aug. 21, 2020 /PRNewswire/ -- Endo International plc (the "Company") (NASDAQ: ENDP) announced today the expiration and final tender results of the previously announced cash tender offer (the "Offer") by its wholly owned subsidiary Endo Finance LLC ("Endo Finance") for any and all…
TUESDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Endo International plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm 2020/08/12 13:33:03 NewMediaWire
Los Angeles, CA - (NewMediaWire) - August 12, 2020 - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Endo International plc (“Endo” or “the Company”) (NASDAQ: ENDP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 8, 2017 and June 10, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before August 18, 2020. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at firstname.lastname@example.org. The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney.
ENDP DEADLINE: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Endo International plc and Lead Plaintiff Deadline: August 18, 2020 2020/08/11 15:00:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Endo International plc ("Endo" or the "Company") (NASDAQ: ENDP) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Endo securities between August 8, 2017, and June 10, 2020, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/endp. This clas
Endo Reports Second-Quarter 2020 Financial Results 2020/08/05 20:30:00 PR Newswire
— Revenues decreased 2% to $688 million compared to prior year — — On July 6, 2020, U.S. FDA approved Qwo™ (collagenase clostridium histolyticum-aaes), the first injectable treatment for cellulite — DUBLIN, Aug. 5, 2020 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today reported…
Endo International's Earnings: A Preview 2020/08/04 10:56:00 Benzinga
Endo International (NASDAQ: ENDP) releases its next round of earnings this Wednesday, August 05. Here's Benzinga's essential guide to Endo …
Shareholder Alert: Robbins LLP Reminds Investors Endo International Plc (ENDP) Sued for Misleading Shareholders 2020/07/16 19:14:00 Business Wire
SAN DIEGO & DUBLIN--(BUSINESS WIRE)---- $ENDP #ClassAction--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Endo International Plc (NYSE: ENDP) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between August 8, 2017 and June 10, 2020. Endo manufactures and sells generic and branded pharmaceuticals in the U.S. and internally, including both generic and branded opioid products. If you suffered a loss as a result of Endo's misc
The Week Ahead In Biotech: J&J Kickstarts Pharma Earnings, Repare Therapeutics IPO 2020/07/12 11:25:00 Benzinga
Biotech stocks advanced in the week ended July 10 amid mixed news flow emerging out of the sector. FDA approved a few drugs, including Endo International …
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Endo International plc of Class Action Lawsuit and Upcoming Deadline – ENDP 2020/07/11 21:53:01 MarketScreener
NEW YORK, July 11, 2020 -- Pomerantz LLP announces that a class action lawsuit has been filed against Endo International plc and certain of its officers. The class action,…
The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For Bankruptcy 2020/07/08 11:31:40 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) AbbVie Inc (NYSE: ABBV ) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) argenx SE – ADR (NASDAQ: ARGX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) (FDA approved the cellulitis drug it had licensed to Endo International PLC (NASDAQ: ENDP )) Cerus Corporation (NASDAQ: CERS ) (announced study results demonstrating that its INTERCEPT Blood System inactivates SARS-CoV-2 in plasma components intended for transfusion) Corvus Pharmaceuticals Inc (NASDAQ: CRVS ) ( announced initiation of a Phase 1 study of a potential coronavirus treatment) Crispr Therapeutics AG (NASDAQ: CRSP ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Immunomedics, Inc.
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates 2020/07/01 14:05:33 Benzinga
The busy calendar of June proved positive for drug approvals, with most scheduled events producing positive outcomes. New molecular entity, or NME, approval for the month totaled two, taking the total NME approvals for the year to 24. Among the NME approvals was Viela Bio Inc's (NASDAQ: VIE ) lead drug Uplinza, which is indicated for neuromyelitis optica spectrum disorder. Although Upliinza will be pitched against Alexion Pharmaceuticals, Inc.'s (NASDAQ: ALXN ) Soliris, the absence of black box warning gives the former an edge, H.C. Wainwright analyst Raghuram Selvaraju said in a note. There were disappointments too. Nabriva Therapeutics PLC's – ADR (NASDAQ: NBRV ) antibiotic Contepa, as expectedly, was handed down a second complete response letter, or CRL, and AbbVie Inc's (NYSE: ABBV ) eye disorder drug also faced rejection at the FDA altar. Here are the key PDUFA dates scheduled for July. Endo Awaits Nod For CCH In Cellulite Company: BioSpecifics Technologies Corp. (NASDAQ: BSTC ) and Endo International PLC (NASDAQ: ENDP ) Type of Application: BLA Candidate: collagenase clostridium histolyticum, or CCH Indication: for treating cellulite Date: July 6 CCH is developed by BioSpecifics and has already been approved for treating Dupuytren's contracture and Peyronie's disease in 2010 and 2013, respectively, and it is marketed in the U.S. by its partner Endo.
World Neuropathy Pain Treatment Market Analysis 2020, Featuring Key Players Assertio Therapeutics Inc., Endo International Plc and Pfizer - ResearchAndMarkets.com 2020/05/21 12:04:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Global Neuropathy Pain Treatment Market 2020-2024" report has been added to ResearchAndMarkets.com's offering. The neuropathy pain treatment market is poised to grow by $ 1702.89 mn during 2020-2024 progressing at a CAGR of 5% during the forecast period. The report on the neuropathy pain treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The market i
Research Report with COVID-19 Forecasts-Global Isosorbide Market 2020-2024 | Rising Demand from Resin and Polymers to Boost Growth | Technavio 2020/05/20 22:00:00 Benzinga Feeds
Technavio has been monitoring the isosorbide market and it is poised to grow by USD 258.77 million during 2020-2024, progressing at a CAGR of almost 10% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200520005685/en/ Technavio has announced its latest market research report titled Global Isosorbide Market 2020-2024 (Graphic: Business Wire) Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Latest Free Sample Report on COVID-19 Impact The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Archer Daniels Midland Co., Endo International Plc, J&K Scientific Ltd., Jinan Hongbaifeng Industry And Trade Co. Ltd., Meryer Chemical Technology Co.
Endo (ENDP) Q1 Earnings Beat on Coronavirus-Led Stockpiling 2020/05/08 09:26:00 Zacks Investment Research
Endo's (ENDP) earnings and sales beat estimates in the first quarter owing to increased customer inventory purchasing due to the COVID-19 pandemic
Endo International (ENDP) Expected to Beat Earnings Estimates: Can the Stock Move Higher? 2020/04/30 16:33:36 Zacks Investment Research
Endo (ENDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
関連キーワード （医薬品 米国株 エンド―・インタ―ナショナル ENDP Endo International plc）